Kimia Biosciences Ltd (KIMIABL) is currently trading at 30.26 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Kimia Bio-sciences Limited, formerly known as Laurel Organics Limited, focuses on manufacturing bulk drugs and APIs at its plant in Gurgaon, Haryana. The company faced financial difficulties and was declared a sick unit during 1998-99, but later recovered and moved out of the BIFR purview by 2005. In 2018, Kimia Biosciences Limited underwent a reverse merger with its holding company, which was holding a majority equity stake. Kimia has maintained its strategic focus on pharmaceuticals, particularly in manufacturing and supplying APIs, strengthening its market position.

Over the past 52 weeks, Kimia Biosciences Ltd has traded between a low of ₹26.09 and a high of ₹86.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Kimia Biosciences Ltd has a market capitalization of approximately 143.17. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Kimia Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.84 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 143.17 Cr, Kimia Biosciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Kimia Biosciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Kimia Biosciences Ltd is 15.84. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.